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of possible effects of the dialysis procedure on the decline ratePredictors of the rate of decline of residual renal function in
between 0 and three months showed that dialysis hypotensionincident dialysis patients.
(P  0.02) contributed to the decline in HD and the presenceBackground. Residual renal function (RRF) influences mor-
of episodes with dehydration contributed in PD (P  0.004).bidity, mortality and quality of life in chronic dialysis patients.
Conclusions. rGFR is better maintained in PD patients thanFew studies have been published on risk factors for loss of RRF
in dialysis patients. These studies were either retrospective, in HD patients. The associated factors such as a higher diastolic
performed in a small number of patients, or estimated GFR blood pressure, proteinuria, dialysis hypotension and dehydra-
without a urine collection. tion can either be treated or avoided.
Methods. We analyzed the decline rates of residual GFR
(rGFR) prospectively in 522 incident HD and PD patients who
had structured follow-up assessments. GFR was measured as
Residual renal function (RRF) is recognized as a sig-the mean of urea and creatinine clearance, calculated from
urine collections. The initial value was obtained 0 to 4 weeks nificant factor influencing morbidity, mortality and qual-
before the start of dialysis. The measurements were repeated 3, ity of life in chronic dialysis patients [1–4]. It contributes
6, and 12 months after the start of dialysis treatment. After loga- substantially to measures of dialysis adequacy such asrithmic transformation, differences in rGFR changes over time
Kt/Vurea and creatinine clearance, especially in peritonealwere analyzed using repeated measurement analysis of variance.
dialysis patients [5, 6]. Also, remnant kidney function in-Results. Baseline factors that were negatively associated with
rGFR at 12 months were a higher diastolic blood pressure (P cludes specific properties that are not easily provided by
0.001) and a higher urinary protein loss (P  0.001). Primary dialysis, such as secretion of organic acids [7] and various
kidney disease did not affect rGFR. Averaged over time, PD pa- endocrine functions [8, 9]. Moreover, the remaining urinetients had a higher rGFR (P  0.001) than HD patients. This
production allows the patients a more liberal fluid intake.relative difference increased over time (P 0.04). Investigation
As RRF has a major impact on outcomes in chronic dialy-
sis patients, its preservation is of vital importance [10, 11].
1 The NECOSAD Study Group included: A.J. Apperloo, R.J. Birnie, Thus far, several studies have been published on risk
M. Boekhout, W.H. Boer, M. van Buren, H.R. Bu¨ller, F.Th. de Charro,
factors for RRF loss in hemodialysis patients [12–16],C.J. Doorenbos, W.T. van Dorp, M.A. van den Dorpel, A. van Es,
W.J. Fagel, G.W. Feith, L.A.M. Frenken, J.A.C.A. van Geelen, P.G.G. and in peritoneal dialysis patients [17–21]. These studies
Gerlag, J.P.M.C. Gorgels, W. Grave, E.C. Hagen, F. de Heer, S.J. reported that RRF is better preserved in peritoneal dial-Hoorntje, R.M. Huisman, K.J. Jager, K. Jie, I. Keur, W.A.H. Koning-
ysis (PD) than in hemodialysis (HD) patients [22–27]. ItMulder, M.I. Koolen, T.K. Kremer Hovinga, A.T.J. Lavrijssen, A.J.
Luik, J.G. van Manen, J. van der Meulen, K.J. Parlevliet, J.B. Rosman, has been postulated that either the use of bioincompati-
F. van der Sande, M.J.M. Schonck, M.M.J. Schuurmans, C.A. Stege- ble hemodialysis membranes or hypovolemic episodesman, P. Stevens, J.G.P. Tijssen, R.M. Valentijn, G, Vastenburg, C.A.
in HD patients are responsible for this difference [24].Verburgh, C.E. Verhagen, H.H. Vincent, P. Vos, and J. Wolters.
However, most studies mentioned above have method-
Key words: hemodialysis, peritoneal dialysis, residual renal function,
ological limitations, including small sample size, inclu-glomerular filtration rate, NECOSAD Study, chronic renal failure,
uremia, prospective cohort study. sion of only a small number of possible predictors or a
retrospective design.
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in this study residual GFR (rGFR) was not actually mea- ment, lost to follow-up), blood, urine, and dialysate sam-
ples in order to calculate rGFR and Kt/Vurea, and bodysured. Baseline GFR was estimated using the Modifica-
tion of Diet in Renal Disease (MDRD) formula and a weight. In HD patients, body weight was measured be-
fore and after each dialysis session. Blood pressure andurine volume greater or less than 200 mL/day was used
as end point for the analyses. Misra et al recently re- body weight in PD patients were measured at a routine
visit in the outpatient clinic. HD treatment characteris-ported on the influence of informative censoring on the
comparison of decline rates of RRF between HD and tics collected were the type of dialysis membrane (syn-
thetic or cellulose derivative), the occurrence of dialysisPD patients [26]. This is the selection bias that occurs if
incomplete follow-up of patients, due to transplantation, hypotension requiring rescue fluid supplementation, di-
alysis frequency, and HD treatment time. Reused dialyz-death or transfer to another modality, is related to the
rate of decline of RRF. ers were not employed in any of the patients. Dialysis
treatment characteristics in PD patients included PDThe influence of patient and treatment characteristics
on the course of RRF was analyzed in a prospective cohort modality [automated or continuous ambulatory perito-
neal dialysis (CAPD)], prescribed dialysate volume, andstudy in the Netherlands on incident HD and PD patients.
Residual GFR was measured 0 to 4 weeks before the the occurrence of periods with clinically evident dehy-
dration since the last measurement.start of dialysis treatment, and at fixed intervals 3, 6 and
12 months thereafter. Moreover, analyses were adjusted In HD patients, blood samples were drawn before and
after a monitoring dialysis session and again before thefor patient dropout during follow-up. Additionally the
hypothesis was tested that hypotensive episodes speed following dialysis session. Urine was collected during the
entire interdialytic interval. The plasma concentrationsup the decline in rGFR in HD patients, and that episodes
of dehydration have the same effect in PD patients. used for the calculation of GFR were the mean of the
concentration after a monitoring dialysis session and that
before the following dialysis session. In PD patients, a
METHODS
24-hour urine and dialysate collection was done prior to
Patients a monitoring visit at the outpatient clinic and a blood
sample was drawn on that visit. rGFR was calculated asNew end-stage renal disease (ESRD) patients, of 18
years and older, from 32 dialysis units in the Netherlands the mean of creatinine and urea clearance and corrected
for body surface area. Therefore, all GFR values are ex-were consecutively included between August 1996 and
November 1999. These patients participated in the Neth- pressed as mL/min/1.73 m2 body surface area. The mean
of urea and creatinine clearance was used, because thiserlands Co-operative Study on the Adequacy of Dialysis,
phase 2 (NECOSAD-2). Compared with data from the provides an accurate approximation of GFR in end-stage
renal failure [29]. In case urea concentrations were miss-Dutch Renal Replacement Registry (RENINE), this co-
hort forms a representative sample of all patients new ing in the urine sample, GFR was estimated by using cre-
atinine clearance in combination with urine productionon RRT in The Netherlands.
Eligible for the present study were patients whose in- according to a recently published formula by our group
[30]: rGFR(mL/min) 0.0086  [0.669 * Creatinine clear-itial GFR, estimated 0 to 4 weeks prior to the start of di-
alysis treatment, was above 1 mL/min/1.73 m2. Informed ance(mL/min)]  [0.785 * Urine production(mL/min)]. HD Kt/
Vurea was determined using a second-generation Daugir-consent was obtained from all patients before inclusion.
das formula [31]. All measurements were performed in
Data collection the participating renal units.
Demographic and baseline data were obtained 0 to
Statistics4 weeks before the start of chronic dialysis treatment.
Baseline data comprised primary kidney disease (PKD), Chi-square tests were used to compare the distribution
of dichotomous and categorical data. Differences in con-comorbidity, height, body weight, blood pressure, use of
antihypertensive medication, serum albumin, and rGFR tinuous variables were tested using t statistics. Based on
a preliminary analysis, rGFR values were logarithmicallycalculated from a 24-hour urine collection. PKD was
classified according to the codes of the European Renal transformed, after adding a constant 1 to prevent the oc-
currence of logarithms of zero. The transformation ofAssociation – European Dialysis and Transplant Associ-
ation (ERA-EDTA) Registry. Comorbidity was defined the data resulted in more normally distributed residuals
and constant variance, a necessary requisite for the statis-in terms of presence of non-renal disease at the time
of inclusion or in the medical history, and was scored tical method used. We analyzed the differences in rGFR
changes over time between PD and HD using repeatedaccording to Davies et al [28]. During follow-up, data
were collected at fixed time points: 3, 6, and 12 months measurement analysis of variance. As a consequence of
the transformation, relative rather than absolute differ-after the start of dialysis. These data included time and
reason of dropout (death, transplantation, change of treat- ences and changes are considered. The analyses were
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Table 1. Baseline characteristicsadjusted for age, sex, primary kidney disease, comorbid-
ity, body mass index, systolic and diastolic blood pressure HD PD
at baseline, use of antihypertensive drugs, dropout, time Number 279 243
Age years 62 (14) 53 (15)aand reason for dropout, including change of treatment.
Sex % male 59 63Time (0, 3, 6 or 12 months), primary kidney disease,
Primary kidney disease %
comorbidity and reason for dropout were used as nomi- Diabetes 14 19
Renovascular 17 13nal variables, all other characteristics as interval (or bi-
Glomerulonephritis 13 14nary) variables. For all variables, except time and reason
Other 56 54
for dropout, an interaction with time of GFR measure- Davies risk score %
No comorbidity 45 55bment also was included in the model, as was an interac-
Intermediate comorbidity 44 39tion between time of and reason for dropout. The covari-
Severe comorbidity 11 6
ance matrix remained unstructured on the basis of a Use of antihypertensives % 74 87a
BMI kg/m2 25.0 (4.3) 24.6 (3.8)preliminary analysis. The handling of dropouts was simi-
Systolic BP mm Hg 150 (24) 146 (23)lar to what has been described by Lysaght et al [24],
Diastolic BP mm Hg 82 (13) 86 (12)a
and Misra et al [26, 32]. However, preliminary analyses Plasma urea mmol/L 36.6 (10.4) 33.1 (8.9)a
Plasma creatinine lmol/L 767 (265) 763 (239)indicated that a non-linear mixed effects model, as was
Serum albumin g/L 37.4 (6.9) 37.9 (6.0)used by these authors, did not fit our data sufficiently.
rGFR mL/min/1.73m2 5.9 (2.8) 6.4 (2.4)d
Associations of baseline variables with rGFR were Urine production L/day 1.8 (0.7) 1.9 (0.6)c
Proteinuria g/day 4.0 (4.1) 4.1 (4.5)analyzed using a hierarchical backward elimination pro-
cedure, starting with the model described above. Time Values are given as means (SD) or %.
a P 0.001, b P 0.03, c P 0.02, d P 0.04 for patients starting with peritonealand type of dialysis were always kept in the model. In
dialysis vs. patients starting with hemodialysis
this perspective, hierarchical means that no main effect
is considered for exclusion, as long as this effect is in-
cluded in any interaction. Otherwise exclusion was not
alysis Kt/Vurea was 2.5  0.7/week. Sixty-one percent ofrestricted. A P value of 0.10 was used as the limit to re-
the patients were treated with synthetic membranes, themain in the model. In view of the large number of factors
others used biocompatible cellulose derivatives. Duringconsidered (21 main effects and interactions), only small
the first three months 27% of the HD patients requiredP values (0.0025) were taken as proof of association.
rescue fluid supplementation for severe dialysis hypoten-The effects of hypotensive episodes and the dialysis
sion. At three months, 63% of the PD patients weremembrane in HD patients, and of under-hydration and
treated with standard 4  2 L exchanges, 17% of theautomated PD in PD patients were studied using multi-
patients dialyzed with less than 8 L and 16% were treatedvariate linear regression analysis. rGFR at three months
with automated PD. Mean  SD dialysis Kt/Vurea in thewas used as outcome parameter for these analyses, as it
PD patients was 1.6  0.4/week. Five percent of the PDappeared that the fall in rGFR was greatest during the
patients had a period of clinically evident dehydration infirst three month interval. First, the effects were studied
the first three months after the start of dialysis treatment.adjusted for baseline GFR only. Secondly, we adjusted
During the follow-up 17 HD patients changed to PDfor baseline GFR, age, sex, comorbidity and PKD. In a
whereas 37 PD patients changed to HD. Six HD patientsthird step additional adjustments were made for Kt/Vurea
and 13 PD patients received a kidney transplant. Thirtyat three months.
HD patients and 9 PD patients died. Fourteen HD pa-
tients and 9 PD patients were lost to follow-up due to
RESULTS various other reasons [such as transfer to a non-partici-
Five hundred and twenty-two patients were included pating center (1 HD), refusal of further participation in
in the study; 279 were initially treated with hemodialysis the study (11 HD, 7 PD)]. Baseline GFR was not differ-
(HD) and 243 patients with peritoneal dialysis (PD). ent among the different outcome groups, nor was there a
Baseline characteristics of these patients are listed in difference in baseline GFR between HD and PD patients
Table 1. PD patients were younger than HD patients within the outcome groups.
and had less comorbidity. PD patients started dialysis The time course of the unadjusted and adjusted rGFR
treatment at a lower plasma urea, a higher GFR, and of the hemodialysis and peritoneal dialysis patients is
with a larger urine production. Moreover, PD patients shown in Figure 1. The adjusted curves were obtained
had a significantly higher diastolic blood pressure, and after back transformation from ln(GFR1). The decline
more PD patients used antihypertensive medication. of rGFR in HD and in PD patients was most pronounced
At three months 48% of the HD patients were treated during the first three months after the start of treatment.
three times per week or more. Mean SD hemodialysis At all time points (0, 3, 6, and 12 months) unadjusted
rGFR values were higher in PD patients when comparedtreatment time was 9.0  2.0 hours/week, and mean di-
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Fig. 1. Unadjusted (A) and adjusted (B) residual glomerular filtration rate (rGFR) values  SE at the start of dialysis treatment, and at 3, 6 and
12 months after the start of dialysis treatment. The adjusted values were obtained after back transformation from ln(rGFR1), which was the
studied variable. Symbols are: (dashed lines) values in the PD patients; (solid lines) rGFR values in the HD patients. Adjustments were made for
baseline GFR, age, primary kidney disease, comorbidity, body mass index, systolic and diastolic blood pressure, use of antihypertensive drugs, drop-
out, time of dropout, and reason of dropout (including change of treatment). Unadjusted rGFR values were significantly higher in PD patients at
all time points. After adjustment, averaged over time, PD patients had a higher rGFR than HD patients (P  0.0001). The relative decline of
rGFR was faster in HD compared to PD patients (P  0.04).
Table 2. Baseline factors associated with rGFR at different time points
Time  ( SE) Effect on index GFRf
Baseline characteristics months ln(GFR1) mL/min/1.73 m2
HD vs. PD 0 m 0.112 (0.034)a 0.64
3 m 0.194 (0.057)a 1.06
6 m 0.292 (0.070)b 1.52
12 m 0.299 (0.080)a 1.55
Diastolic BP (10 mm Hg) Any 0.07 (0.013)b 0.41
No comorbidity vs. severe comorbidity Any 0.165 (0.057)c 0.91
Intermediate vs. severe comorbidity Any 0.164 (0.057)c 0.91
Use of antihypertensives yes vs. no Any 0.084 (0.040)d 0.53
Serum albumin 5 g/L Any 0.036 (0.012)c 0.22
Ln(proteinuria) ln(g/day) 0 m 0.070 (0.017)e 0.44
3 m 0.0112 (0.028)e 0.07
6 m 0.0640 (0.035)e 0.37
12 m 0.0838 (0.040)e 0.48
In view of the large number of factors considered, only P values 0.0025 were taken as proof of association.
a P  0.001, b P  0.0001, c P  0.01, d P  0.04, e P  0.0001 (interaction with time)
f Index GFR is 5 mL/min/1.73 m2, effect in mL/min/1.73 m2. The effect on rGFR is given of a difference in the baseline factor by the number of units as given in
the first column.
to HD patients. Also, after adjustment for baseline vari- diastolic blood pressure and proteinuria were found to
be associated with rGFR (P 0.0025, Methods section).ables and dropout, averaged over time, PD patients had
a 30% (SE 8%) higher rGFR than HD patients (P  It implies that an increase in diastolic blood pressure of
10 mm Hg in a patient with the index rGFR will result0.0001). Moreover, after an additional adjustment for
baseline rGFR the relative difference increased over in a decrease with 0.4 mL/min. At all time points, rGFR
decreased with increasing diastolic blood pressure attime (P  0.04), especially during the first six months.
At that time, the rGFR of PD patients had decreased baseline. rGFR at baseline and at three months increased
with proteinuria at baseline, but rGFR at 6 and 1220% (SE 7%) less than that of HD patients. However,
the absolute decrease in both groups was about equal months decreased with proteinuria at baseline. No evi-
dence of selective dropout was found.as shown in Figure 1.
Table 2 shows the results of the backward elimination To further elucidate dialysis related mechanisms re-
sponsible for the decline in rGFR, we analyzed the effectprocedure. The effect of the confounders is given for the
studied outcome parameter ln(rGFR1). To give more of hypotensive episodes and the dialysis membrane in
HD patients, and of dehydration and automated PD ininsight in the magnitude of effects of confounders, results
also are expressed in mL/min in a situation were the PD patients on rGFR at three months. The three month
period was chosen because it comprised the most pro-rGFR was set at 5 mL/min/1.73 m2 (index rGFR). Only
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Table 4. Effect of dehydration on rGFR at three months in PDTable 3. Effect of hypotensive episodes on rGFR at three months
in HD patients at different levels of adjustment patients at different levels of adjustment
PD patients: underhydration SEa PHD patients: hypotensive episodes SEa P
Model 1; Adjusted for baseline GFR 0.940.32 0.003 Model 1; Adjusted for baseline GFR 1.930.64 0.003
Model 2; Adjusted for 1, and for age, sex,Model 2; Adjusted for 1, and for age, sex,
PKD, and comorbidity 0.950.32 0.004 PKD, and comorbidity 1.940.64 0.003
Model 3; Adjusted for 1, 2, and for dialysisModel 3; Adjusted for 1, 2, and for dialysis
Kt/Vurea at 3 months 0.760.32 0.02 Kt/Vurea at 3 months 1.840.63 0.004
a gives the effect in mL/min/1.73 m2 on rGFR at 3 months a gives the effect in mL/min/1.73 m2 on rGFR at 3 months
weeks before the start of dialysis. This strict entry crite-nounced decline in rGFR. Both the occurrence of dialy-
rion can provide an explanation for the higher declinesis sessions complicated by hypotension in HD patients
rates found in the present study, because the fall in rGFR(Table 3), and the presence of periods with clinically
was greatest just after the start of dialysis. It is unlikelyevident dehydration in PD patients (Table 4) were nega-
that the greater fall in rGFR in our study is due to patienttively associated with rGFR at three months, even after
selection, as we applied only two selection criteria: pa-correction for possible confounders. The type of dialysis
tients had to be 18 years or older, and rGFR 0 to 4 weeksmembrane in HD patients, and PD modality showed no
before the start of dialysis treatment had to be aboverelationship with rGFR at three months.
1 mL/min/1.73 m2. Although the latter may have caused
a regression toward the mean effect, this effect should
DISCUSSION be limited because the vast majority of the patients had
The present prospective analysis on the course of re- a baseline rGFR well above the inclusion limit and the
sidual renal function in a large number of patients has measurement error could be estimated to be less than
confirmed that rGFR is better maintained in peritoneal 20%. Moreover, the biasing effect of dropout was limited
dialysis patients when compared to hemodialysis pa- by analyzing rGFR values of patients until the time of
tients. Moreover, diastolic hypertension, proteinuria in dropout and by adjusting for dropout in the analyses
the long term, and hemodialysis hypotension as well as [26, 32]. When only patients who stay on treatment are
dehydration in PD patients were identified as risk factors analyzed and dropout is somehow related to a faster
for the loss of rGFR. decline, the decline rates may be underestimated.
A faster decline of rGFR in HD patients compared Compared to other publications, the difference in de-
to PD patients has been reported in all previous publica- cline rates of rGFR between HD and PD patients was
tions on this subject [22–24, 26, 27]. Details of these pub- only modest in our study, although still significant. This
lications are shown in Table 5. These studies were either difference was further reduced after adjustments for case-
retrospective, had a small sample size, or both. Compari- mix and informative censoring. In general, observational
son of the results is difficult because of different designs, studies are likely to inflate treatment effects [33, 34].
statistical methods, and estimations of rGFR. In case de- However, examples in recent reports have shown that
cline rates were not given in the publications themselves, that is not always the case for large well-designed pro-
we estimated them from the mean values given at 0, 6, spective cohort studies [35, 36]. Due to the large number
and 12 months. In contrast to most other studies, we mea- of patients studied, we were able to adjust for all known
sured baseline rGFR before the start of dialysis. The de- baseline determinants of the decline of rGFR, including
cline rates in the previous studies ranged from 1.2%/ possible confounding effects of selective dropout. How-
month to 2.91%/month in PD patients and from 5.8%/ ever, we cannot fully exclude some remaining confound-
month to 7.0%/month in HD patients. The decline rates ing in unobserved determinants. Yet, this is unlikely to be
found in the present study were 1.5 to 2 times higher the case. Comparing the observed effect of dialysis mod-
than those calculated from other studies. A possible ex- ality on the rate of decline in our study with findings in
planation may be that most other studies used creatinine the literature makes it less likely that our findings do
clearance, which overestimates rGFR due to tubular se- over- or underestimate the effect of dialysis modality.
cretion of creatinine. The only other study is that of In addition, several studies have shown that residual re-
Misra et al in which the mean of urea and creatinine nal function loss in HD patients is accelerated by the use
clearance also was used [26]. The difference with that of bioincompatible cellulosic hemodialysis membranes
retrospective study is not extremely large, especially [14–16]. Most comparative analyses were performed be-
when taking into account that most rGFR measurements tween HD patients using bioincompatible membranes and
were done after the start of dialysis. Only in our study CAPD patients, whereas in our study all HD patients used
biocompatible cellulose derivatives and synthetic hemo-all patients had proper baseline measurements 0 to 4
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dialysis membranes. This may be an additional explana- minants for the decrease in rGFR. Several [14–16, 27],
although not all [13, 25], studies showed an addi-tion for the larger difference found in previous studies.
Besides dialysis modality, we found diastolic blood pres- tional effect of the type of dialysis membrane in HD pa-
tients. We could not find such an effect, probably becausesure and proteinuria to be associated with changes in
rGFR from 0 to 12 months. Baseline proteinuria espe- all our patients used biocompatible membranes. In some
[20, 41], though not all [42, 43] studies, the decline ofcially conducts its negative effect after six months,
whereas it was positive in the first six months. In studies rGFR has been reported greater in patients treated with
automated peritoneal dialysis than in patients treatedthat have reported on factors affecting the residual renal
function in dialysis patients [12–21, 24, 25], no negative with CAPD. We could not find such an effect.
Residual GFR is better maintained in PD patients thaneffect of high blood pressure or proteinuria has been
described. However, a positive effect of a higher mean in HD patients, although the effect of dialysis modality in
this large, controlled, prospective cohort study is smallerarterial pressure was found by Moist et al in their HD
subpopulation [25]. In their study post-dialysis blood than in previous observations by others. As rGFR is a
significant factor influencing morbidity, mortality andpressure was measured 60 days after the start of dialysis.
Therefore, this finding probably reflects the negative ef- quality of life in chronic dialysis patients, its preservation
is of vital importance. Our findings provide tools for thefect of a low blood pressure resulting from post-dialysis
volume depletion due to excessive fluid removal. The preservation of rGFR, because conditions such as a
higher diastolic blood pressure, proteinuria, dialysis hy-results of the present study are in concordance with data
from the literature in predialysis chronic renal failure potension and dehydration can be treated or avoided.
patients. In that population the negative effects of higher
blood pressure [37, 38], and proteinuria [38, 39] are well ACKNOWLEDGMENTS
documented. Although the dialysis procedure may be This work was supported by grants from the Dutch Kidney Foun-
dation (E.018) and the Dutch National Health Insurance Boardthe source of additional risk factors, it is conceivable
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Egelenburg 73, 1081 GJ Amsterdam, The Netherlands.the initiation of dialysis. Other factors related to rGFR
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